3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
4
Recurrence
3
Basal Cell Nevus Syndrome
3
Skin Neoplasms
2
Multiple Myeloma
2
Medulloblastoma
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pancreatic Diseases
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hepatoblastoma
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Glioma
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Bone Marrow Diseases
1
Blood Platelet Disorders
1
Blood Coagulation Disorders
1
Astrocytoma
1
Interventions
Cyclophosphamide
34
fludarabine
25
fludarabine phosphate
24
Tacrolimus
24
Mycophenolic Acid
23
Whole-Body Irradiation
22
Busulfan
15
Methotrexate
12
Melphalan
12
Granulocyte Colony-Stimulating Factor
12
Antilymphocyte Serum
12
thymoglobulin
11
Cyclosporine
11
Stem Cell Transplantation
10
Filgrastim
10
Rituximab
9
Thiotepa
7
Peripheral Blood Stem Cell Transplantation
7
Nivolumab
7
Dexamethasone
7
trametinib
6
Radiotherapy
6
Mesna
6
Cytarabine
6
Prednisone
5
Calcium Dobesilate
5
Bortezomib
5
Azacitidine
5
Alemtuzumab
5
Voriconazole
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hematologic Neoplasms
×
sonidegib
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts